

DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER ENDED 30TH JUNE, 2015

(₹ in Lakhs)

Sl No.	Particulars	STANDALONE			
		Unaudited			Audited
		Quarter ended 30.06.2015	Quarter ended 31.03.2015	Quarter ended 30.06.2014	Year Ended 31.03.2015
	(1)	(2)	(3)	(4)	(5)
1	Income from operations				
	(a) Net Sales/Income from operations (Net of Excise Duty)	80691	81469	63976	307230
	(b) Other Operating Income	185	240	290	1171
	Total Income from operations (net)	80876	81709	64266	308401
2	<u>Expenditure:</u>				
	a. Cost of materials consumed	35567	39186	29672	144627
	b. Purchases of stock-in-trade	0	0	0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3513)	(9457)	(4778)	(23083)
	d. Employee benefits expense	8033	7890	6018	28315
	e. Depreciation and amortization expense	2892	4454	3326	13585
	f. Other Expenses	10804	12578	9837	42337
	Total Expenses	53783	54651	44075	205781
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	27093	27058	20191	102620
4	Other Income	3399	1254	1269	4284
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	30492	28312	21460	106904
6	Finance Costs	22	59	36	186
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	30470	28253	21424	106718
8	Exceptional items	0	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	30470	28253	21424	106718
10	Tax Expense:	6152	5362	4631	22012

11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	24318	22891	16793	84706
12	Extra-ordinary items (net of tax expense)	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	24318	22891	16793	84706
14	Share of profit / (loss) of associates	0	0	0	0
15	Minority Interest	0	0	0	0
16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	24318	22891	16793	84706
17	Paid-up Equity Share Capital (Face Value : ₹. 2 per share)	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				353541
19.i	Earnings per Share (before extraordinary items) (of ₹. 2/- each) (not annualized):				
	a) Basic	18.32	17.25	12.65	63.82
	b) Diluted	18.32	17.25	12.65	63.82
19.ii	Earnings per Share (after extraordinary items) (of ₹. 2/- each) (not annualized):				
	a) Basic	18.32	17.25	12.65	63.82
	b) Diluted	18.32	17.25	12.65	63.82

A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding - No. of shares - Percentage of shareholding	63603674 47.92%	63603674 47.92%	63603674 47.92%	63603674 47.92%
2	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	Nil 69130616 100% 52.08%	Nil 69130616 100% 52.08%	Nil 69130616 100% 52.08%	Nil 69130616 100% 52.08%

	Particulars	Quarter ended 30th June 2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	8
	Disposed off during the quarter	8
	Remaining unresolved at the end of the quarter	Nil

NOTES:

1. The above results for the quarter ended 30th June 2015, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 8th August, 2015 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

	Quarter ended 30.06.2015	Quarter ended 31.03.2015	Quarter ended 30.06.2014	Year Ended 31.03.2015
	₹. Lakhs	₹. Lakhs	₹. Lakhs	₹. Lakhs
Forex gain/(loss)	2122	(1787)	135	(105)

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/period have been regrouped wherever necessary.
6. Figures in respect of the results for preceding quarter ended 31st March, 2015 are the balancing figures between audited figures in respect of the financial year ended 31st March, 2015 and the published year-to-date figures upto the third quarter ended 31st December, 2014.
7. On the eve of 25th year of formation of the company, the Board is pleased to recommend issue of Bonus equity shares in the ratio of 1:1 i.e., one (1) equity share for every one (1) equity share held, subject to approval by the members of the company.

for Divi's Laboratories Limited

Place: Hyderabad
Date: 8th August, 2015

Dr. Murali K. Divi
Chairman & Managing Director